The Canadian Journal of Psychiatry

Last updated

History

The journal was established in January 1956 as The Canadian Psychiatric Association Journal/La revue de l'association canadienne de psychiatrie. [1] The journal started as a quarterly publication, under its founding editor-in-chief, F. Rhodes Chalke. [2] He was succeeded in 1972 by Frederick Lowy, who remained until 1976. [3] Publication changed from bimonthly in 1974 to eight issues a year in 1975. Edward Kingstone took over as editor in 1977. [4] The journal obtained its current name in 1979. [5] He was succeeded in 1995 by Quentin Rae-Grant, who remained until 2004. [6] In 2004, the journal started publishing monthly. [7] Joel Paris became editor-in-chief in October 2004, continuing this role for 10 years. [8] The current editor is Scott Patten, who has been in this role since 2014 [9] The journal published 14 issues per year in 2005 and 2006, but returned to a monthly frequency in 2007. [10] An electronic version of the journal was launched in January 2012. Because of the advertising, web access was restricted to members only in 2012 to avoid direct-to-consumer advertising. Articles had been freely accessible since 2002. In 2013, paid subscribers were also allowed access. [11] As the Journal is now published by SAGE, access is governed by that company's policies. All members of the Canadian Psychiatric Association receive a subscription as a membership benefit.

Abstracting and indexing

The journal is abstracted and indexed in Index Medicus/MEDLINE/PubMed, EMBASE, PsycINFO, Science Citation Index, EBSCO, and ProQuest. According to the Journal Citation Reports , the journal has a 2020 impact factor of 4.356, ranking it 33rd out of 144 SSCI journals in the category "Psychiatry". [12] This places it in the first quartile of Psychiatry journals. In the SCIE index, it is ranked 51 out of 156.

Online archives

The complete archive of the journal from 1956 to the present is available online. Full-text articles had been freely accessible since 2002. However, in January 2012, online access was restricted for six months, except for members of the Canadian Psychiatric Association who get immediate online access. In 2013, subscribers were allowed immediate online access.

Notable articles

Examples of highly cited articles (>200 times) published in the journal are: [13]

See also

Related Research Articles

<span class="mw-page-title-main">Antipsychotic</span> Class of medications

Antipsychotics, also known as neuroleptics, are a class of psychotropic medication primarily used to manage psychosis, principally in schizophrenia but also in a range of other psychotic disorders. They are also the mainstay together with mood stabilizers in the treatment of bipolar disorder.

<span class="mw-page-title-main">Bipolar disorder</span> Mental disorder that causes periods of depression and abnormally elevated mood

Bipolar disorder, previously known as manic depression, is a mental disorder characterized by periods of depression and periods of abnormally elevated mood that each last from days to weeks. If the elevated mood is severe or associated with psychosis, it is called mania; if it is less severe, it is called hypomania. During mania, an individual behaves or feels abnormally energetic, happy or irritable, and they often make impulsive decisions with little regard for the consequences. There is usually also a reduced need for sleep during manic phases. During periods of depression, the individual may experience crying and have a negative outlook on life and poor eye contact with others. The risk of suicide is high; over a period of 20 years, 6% of those with bipolar disorder died by suicide, while 30–40% engaged in self-harm. Other mental health issues, such as anxiety disorders and substance use disorders, are commonly associated with bipolar disorder.

<span class="mw-page-title-main">Bipolar I disorder</span> Bipolar disorder that is characterized by at least one manic or mixed episode

Bipolar I disorder is a type of bipolar spectrum disorder characterized by the occurrence of at least one manic episode, with or without mixed or psychotic features. Most people also, at other times, have one or more depressive episodes, and all experience a hypomanic stage before progressing to full mania.

<span class="mw-page-title-main">Asperger syndrome</span> Former neurodevelopmental diagnosis

Asperger syndrome (AS), also known as Asperger's, is a neurodevelopmental condition characterized by significant difficulties in social interaction and nonverbal communication, along with restricted and repetitive patterns of behaviour and interests. The syndrome is no longer recognised as a diagnosis in itself, having been merged with other conditions into autism spectrum disorder (ASD). It was considered to differ from other diagnoses that were merged into ASD by relatively unimpaired spoken language and intelligence.

<span class="mw-page-title-main">Clozapine</span> Atypical antipsychotic medication

Clozapine is a psychiatric medication and is the first atypical antipsychotic. It is primarily used to treat people with schizophrenia and schizoaffective disorder who have had an inadequate response to other antipsychotics or who have been unable to tolerate other drugs due to extrapyramidal side effects. It is also used for the treatment of psychosis in Parkinson's disease. Clozapine is regarded as the gold-standard treatment when most other medications are ineffective and its use is recommended by multiple international treatment guidelines, after resistance to earlier neuroleptic treatment is established.

<span class="mw-page-title-main">Electroconvulsive therapy</span> Medical procedure in which electrical current is passed through the brain

Electroconvulsive therapy (ECT) is a psychiatric treatment where a generalized seizure is electrically induced to manage refractory mental disorders. Typically, 70 to 120 volts are applied externally to the patient's head, resulting in approximately 800 milliamperes of direct current passing between the electrodes, for a duration of 100 milliseconds to 6 seconds, either from temple to temple or from front to back of one side of the head. However, only about 1% of the electrical current crosses the bony skull into the brain because skull impedance is about 100 times higher than skin impedance.

<span class="mw-page-title-main">Mood disorder</span> Group of conditions characterised by a disturbance in mood

A mood disorder, also known as an affective disorder, is any of a group of conditions of mental and behavioral disorder where a disturbance in the person's mood is the main underlying feature. The classification is in the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Classification of Diseases (ICD).

<span class="mw-page-title-main">Psychiatric medication</span> Medication used to treat mental disorders

A psychiatric or psychotropic medication is a psychoactive drug taken to exert an effect on the chemical makeup of the brain and nervous system. Thus, these medications are used to treat mental illnesses. These medications are typically made of synthetic chemical compounds and are usually prescribed in psychiatric settings, potentially involuntarily during commitment. Since the mid-20th century, such medications have been leading treatments for a broad range of mental disorders and have decreased the need for long-term hospitalization, thereby lowering the cost of mental health care. The recidivism or rehospitalization of the mentally ill is at a high rate in many countries, and the reasons for the relapses are under research.

<span class="mw-page-title-main">Panic attack</span> Period of intense fear

Panic attacks are sudden periods of intense fear and discomfort that may include palpitations, sweating, chest pain or chest discomfort, shortness of breath, trembling, dizziness, numbness, confusion, or a feeling of impending doom or of losing control. Typically, symptoms reach a peak within ten minutes of onset, and last for roughly 30 minutes, but the duration can vary from seconds to hours. Although they can be extremely frightening and distressing, panic attacks themselves are not physically dangerous.

Schizoaffective disorder is a mental disorder characterized by abnormal thought processes and an unstable mood. This diagnosis is made when the person has symptoms of both schizophrenia and a mood disorder: either bipolar disorder or depression. The main criterion for a diagnosis of schizoaffective disorder is the presence of psychotic symptoms for at least two weeks without any mood symptoms present. Schizoaffective disorder can often be misdiagnosed when the correct diagnosis may be psychotic depression, bipolar I disorder, schizophreniform disorder, or schizophrenia. It is imperative for providers to accurately diagnose patients, as treatment and prognosis differ greatly for most of these diagnoses.

<span class="mw-page-title-main">Cholecystokinin</span> Hormone of the gastrointestinal system

Cholecystokinin is a peptide hormone of the gastrointestinal system responsible for stimulating the digestion of fat and protein. Cholecystokinin, formerly called pancreozymin, is synthesized and secreted by enteroendocrine cells in the duodenum, the first segment of the small intestine. Its presence causes the release of digestive enzymes and bile from the pancreas and gallbladder, respectively, and also acts as a hunger suppressant.

Alexithymia is a neuropsychological phenomenon expressing important difficulties in identifying and describing the experienced emotions by oneself or others. It also involves emotional issues in terms of social attachment and interpersonal relations. There is no scientific agreement whether this neuropsychological phenomenon is a personality trait, a medical symptom or eventually a mental disorder.

<span class="mw-page-title-main">Depression (mood)</span> State of low mood and aversion to activity

Depression is a mental state of low mood and aversion to activity. It affects more than 280 million people of all ages. Depression affects a person's thoughts, behavior, feelings, and sense of well-being. Depressed people often experience loss of motivation or interest in, or reduced pleasure or joy from, experiences that would normally bring them pleasure or joy. Depressed mood is a symptom of some mood disorders such as major depressive disorder and dysthymia; it is a normal temporary reaction to life events, such as the loss of a loved one; and it is also a symptom of some physical diseases and a side effect of some drugs and medical treatments. It may feature sadness, difficulty in thinking and concentration and a significant increase or decrease in appetite and time spent sleeping. People experiencing depression may have feelings of dejection or hopelessness and may experience suicidal thoughts. It can either be short term or long term.

Child and adolescent psychiatry is a branch of psychiatry that focuses on the diagnosis, treatment, and prevention of mental disorders in children, adolescents, and their families. It investigates the biopsychosocial factors that influence the development and course of psychiatric disorders and treatment responses to various interventions. Child and adolescent psychiatrists primarily use psychotherapy and/or medication to treat mental disorders in the pediatric population.

Robert Michael Bagby is a Canadian psychologist, senior clinician scientist and director of clinical research at the Centre for Addiction and Mental Health (CAMH). He is a full professor in the Department of Psychiatry, University of Toronto. He became a full professor of psychology at the University of Toronto Scarborough campus in July 2011.

<span class="mw-page-title-main">Cholecystokinin A receptor</span> Protein-coding gene in the species Homo sapiens

The Cholecystokinin A receptor is a human protein, also known as CCKAR or CCK1, with CCK1 now being the IUPHAR-recommended name.

<span class="mw-page-title-main">CCK-4</span> Anxiogenic agent

Cholecystokinin tetrapeptide (CCK-4, tetragastrin, Trp-Met-Asp-Phe-NH2) is a peptide fragment derived from the larger peptide hormone cholecystokinin. Unlike cholecystokin which has a variety of roles in the gastrointestinal system as well as central nervous system effects, CCK-4 acts primarily in the brain as an anxiogenic, although it does retain some GI effects, but not as much as CCK-8 or the full length polypeptide CCK-58.

<span class="mw-page-title-main">CI-988</span> Chemical compound

CI-988 (PD-134,308) is a drug which acts as a cholecystokinin antagonist, selective for the CCKB subtype. In animal studies it showed anxiolytic effects and potentiated the analgesic action of both morphine and endogenous opioid peptides, as well as preventing the development of tolerance to opioids and reducing symptoms of withdrawal. Consequently, it was hoped that it might have clinical applications for the treatment of pain and anxiety in humans, but trial results were disappointing with only minimal therapeutic effects observed even at high doses. The reason for the failure of CI-988 and other CCKB antagonists in humans despite their apparent promise in pre-clinical animal studies is unclear, although poor pharmacokinetic properties of the currently available drugs are a possible explanation, and CCKB antagonists are still being researched for possible uses as adjuvants to boost the activity of other drugs.

<span class="mw-page-title-main">Social anxiety disorder</span> Anxiety disorder associated with social situations

Social anxiety disorder (SAD), also known as social phobia, is an anxiety disorder characterized by sentiments of fear and anxiety in social situations, causing considerable distress and impaired ability to function in at least some aspects of daily life. These fears can be triggered by perceived or actual scrutiny from others. Individuals with social anxiety disorder fear negative evaluations from other people.

<span class="mw-page-title-main">Panic disorder</span> Anxiety disorder characterized by reoccurring unexpected panic attacks

Panic disorder is a mental and behavioral disorder, specifically an anxiety disorder characterized by reoccurring unexpected panic attacks. Panic attacks are sudden periods of intense fear that may include palpitations, sweating, shaking, shortness of breath, numbness, or a feeling that something terrible is going to happen. The maximum degree of symptoms occurs within minutes. There may be ongoing worries about having further attacks and avoidance of places where attacks have occurred in the past.

References

  1. McKerracher DG. President's foreword. Can. Psychiatr. Assoc. J. 1956; 1(1):1.
  2. Paris, J (2000). "Canadian psychiatry across 5 decades: From clinical inference to evidence-based practice". Canadian Journal of Psychiatry. 45 (1): 34–9. doi: 10.1177/070674370004500105 . PMID   10696487.
  3. Lowy, FH (1976). "The state of the speciality". Canadian Psychiatric Association Journal. 21 (8): 505–7. doi: 10.1177/070674377602100801 . PMID   1024692.
  4. Kingstone E (1977). "Changing of the guard". Can. Psychiatr. Assoc. J. 22 (1): 1–2. doi: 10.1177/070674377702200101 .
  5. Kingstone E. A time for change. Can. J. Psychiatry 1979;24(1):2.
  6. Rae-Grant Q. Plus ça change, plus c'est la même chose. Can. J. Psychiatry 1995;40(8):433-434.
  7. Rae-Grant Q (2003). "Looking back, moving forward". Can. J. Psychiatry. 48 (11): 715. doi:10.1177/070674370304801101. PMC   4435326 . PMID   26157865.
  8. Paris J (2005). "Canadian Journal of Psychiatry: New Editor and New Policies". Can J Psychiatry. 50 (1): 1. doi: 10.1177/070674370505000101 .
  9. Can. J. Psychiatry 2015;60(1):1-3. The Canadian Journal of Psychiatry in 2014 and beyond. http://publications.cpa-apc.org/media.php?mid=1832. Date accessed March 21, 2016.
  10. Paris J (2007). "The Canadian Journal of Psychiatry in 2007: thanks to our reviewers in 2006". Can. J. Psychiatry. 52 (1): 1–2. doi: 10.1177/070674370705200101 .
  11. Paris, J (2013). "Bigger and better: Expanding in reviews and the electronic era". Canadian Journal of Psychiatry. 58 (1): 1–2. doi: 10.1177/070674371305800101 . PMID   23327748.
  12. "Journals Ranked by Impact: Psychiatry". 2020 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2021.
  13. "Canadian Journal of Psychiatry". Web of Knowledge. Web of Science (Science ed.). Thomson Reuters. 2013.